Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from January 31, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on May 1, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$108.00 – $111.00Entry zone — fair-value band

$110.27Published — price the day we called it

$119.09Target — the price the thesis aimed for

$125.14Peak — highest point inside the window, not a realized return

$112.16Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 4 days.

Peak price

$125.14

peak on February 25, 2026 — not a realized return

Peak gain

+13.5%

peak, from the publication price

Window close

$112.16

end-of-window price, context only

Days to target

Window

January 31, 2026 – May 1, 2026

The thesis — published January 31, 2026

Predicted growth

+8%

over the measurement window

Target price

$119.09

the price the thesis aimed for

Entry zone

$108.00 – $111.00

the fair-value band we waited for

Price at publication

$110.27

published January 31, 2026

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck is getting attention because it keeps announcing cancer drug partnerships and other deals. That news helps the stock move higher for a while, even if the underlying business is steady. The risk is the move is driven by attention, so it can reverse if investors lose interest. A good approach is to buy on short dips and sell into strength rather than expect constant gains.

Primary drivers

Partnerships keep new developments in the news and draw buyers
Health care often holds up when markets get shaky, helping demand
Big investors often buy after visible deal activity, lifting shares
Buying on dips lets you enter with lower risk during choppy periods

How it played out

MRK: target reached in 4 days

Lyra published MRK at 110.27 on 2026-01-31 with an 8% expected gain and a 119.09 target. The thesis pointed to cancer drug partnerships and other deals keeping the stock in the news, health care demand during shaky markets, visible deal activity drawing big investors, and buying on dips during choppy periods.

Inside the window, the stock reached the target in 4 days. It later peaked at 125.14 on 2026-02-25, a 13.5% gain. By 2026-05-01, it ended at 112.16. The thesis played out early, then gave back part of the move.

What happened during the window

On 2026-02-03, MarketWatch reported that Merck gave 2026 guidance below analyst expectations while fourth-quarter revenue rose from the prior year. On 2026-03-25, Cinco Días reported that Merck was close to a cash deal to acquire Terns Pharmaceuticals.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals